Abstract A145: Prostate cancer disparities in sub-Saharan Africa: Epidemiology, genomics, and health system gaps
TL;DR
Strengthening cancer registries, expanding early detection strategies, improving radiotherapy and systemic treatment capacity, and increasing African participation in genomic research are critical steps toward reducing prostate cancer mortality and advancing cancer health equity in SSA.
Abstract
Prostate cancer is the most commonly diagnosed cancer and the leading cause of cancer-related mortality among men in sub-Saharan Africa (SSA). According to GLOBOCAN 2022, an estimated 86,364 new prostate cancer cases and 48,786 deaths occurred in SSA, with a mortality-to-incidence ratio around 0.56, markedly higher than in high-income regions. Despite lower reported incidence compared to high-income countries, mortality remains disproportionately high, reflecting profound cancer health disparities. This review synthesizes epidemiologic patterns, biological risk factors, health system barriers, and research gaps contributing to poor outcomes in SSA. A narrative review of peer-reviewed studies, population-based cancer registry reports, and global cancer databases published between 2005 and 2025 was conducted. Studies addressing incidence trends, stage at diagnosis, genomic susceptibility loci, screening uptake, treatment access, and survival outcomes in SSA populations were included. Across multiple hospital- and registry-based studies, 65–90% of patients in SSA present with locally advanced or metastatic disease at diagnosis, compared to less than 20% in many high-income settings. Five-year relative survival in SSA is estimated to range between 30–50%, markedly lower than survival rates exceeding 95% for localized disease in high-resource countries. Screening uptake remains limited; population-based PSA screening programs are limited, and opportunistic testing rates are low. Radiotherapy availability in SSA averages fewer than 1 machine per million population in many countries, well below International Atomic Energy Agency recommendations. Genomic investigations involving approximately 8,000 African men have identified at least 15 genome-wide significant susceptibility loci, including variants at 8q24.21, 6q22.1, and 11q13.3. African-enriched variants such as rs72725854 at 8q24 are associated with markedly elevated risk of early-onset disease, with reported odds ratios exceeding 30 in high-risk families. However, African-derived samples represent less than 5% of participants in major prostate cancer genomic consortia, limiting the development of ancestry-informed risk models. Prostate cancer disparities in SSA are driven by intersecting biological susceptibility, late-stage presentation, limited screening infrastructure, and restricted access to curative therapy. Underrepresentation in genomic research further constrains precision oncology advances. Strengthening cancer registries, expanding early detection strategies, improving radiotherapy and systemic treatment capacity, and increasing African participation in genomic research are critical steps toward reducing prostate cancer mortality and advancing cancer health equity in SSA. Ayodeji O. Ojetunde. Prostate cancer disparities in sub-Saharan Africa: Epidemiology, genomics, and health system gaps [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr A145.